We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
176
Replimune Group
REPL
$994M
$96.6K 0.01%
+10,400
New +$90.7K
PLRX icon
177
Pliant Therapeutics
PLRX
$65M
$95.3K 0.01%
+82,189
New +$116K
SNDX icon
178
Syndax Pharmaceuticals
SNDX
$1.77B
$93.7K 0.01%
+10,000
New +$110K
EPIX
179
DELISTED
ESSA Pharma
EPIX
$85K 0.01%
+50,000
New +$84.4K
AUPH icon
180
Aurinia Pharmaceuticals
AUPH
$1.95B
$84.7K 0.01%
+10,000
New +$80.2K
STTK icon
181
Shattuck Labs
STTK
$704M
$81.5K 0.01%
102,948
+792
+0.8% +$768
RLMD icon
182
Relmada Therapeutics
RLMD
$571M
$78K 0.01%
+130,000
New +$66.7K
BCAB icon
183
BioAtla
BCAB
$5.53M
$67.5K 0.01%
+3,410
New +$69.1K
CMPX icon
184
Compass Therapeutics
CMPX
$340M
$65K 0.01%
+25,000
New +$51.6K
BOLT icon
185
Bolt Biotherapeutics
BOLT
$7.59M
$62.4K 0.01%
10,823
-1,425
-12% -$9.43K
ZNTL icon
186
Zentalis Pharmaceuticals
ZNTL
$352M
$58K 0.01%
+50,000
New +$65.9K
NXTC icon
187
NextCure
NXTC
$21.4M
$54.3K 0.01%
9,834
-167
-2% -$896
CASI
188
DELISTED
CASI Pharmaceuticals
CASI
$52.1K 0.01%
44,120
-3,300
-7% -$6.05K
AAM.WS
189
DELISTED
AA Mission Acquisition Corp Warrants
AAM.WS
$49.7K 0.01%
505,099
– –
ELDN icon
190
Eledon Pharmaceuticals
ELDN
$266M
$45.8K 0.01%
16,900
+300
+2% +$900
IBIO icon
191
iBio
IBIO
$69.5M
$41.8K 0.01%
+54,819
New +$59.5K
OVID icon
192
Ovid Therapeutics
OVID
$489M
$38.2K 0.01%
115,867
– –
ASPCR
193
A SPAC III Acquisition Corp Right
ASPCR
$36.5K 0.01%
215,000
– –
MURA
194
DELISTED
Mural Oncology
MURA
$29.3K ﹤0.01%
+11,855
New +$27.9K
RNXT icon
195
RenovoRx
RNXT
$47.8M
$26.2K ﹤0.01%
19,889
-459,994
-96% -$524K
OKUR
196
OnKure Therapeutics
OKUR
$168M
$23.9K ﹤0.01%
10,000
– –
PEPG icon
197
PepGen
PEPG
$137M
$22.6K ﹤0.01%
20,352
– –
NERV icon
198
Minerva Neurosciences
NERV
$203M
$21.3K ﹤0.01%
+12,406
New +$20.3K
JVSAR
199
DELISTED
JV SPAC Acquisition Corp. Right
JVSAR
$20.9K ﹤0.01%
24,000
-6,000
-20% -$2.49K
PRQR icon
200
ProQR Therapeutics
PRQR
$278M
$20.4K ﹤0.01%
10,000
-10,394
-51% -$16.9K
6 7
8
9 10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.